Home / Clinical Laboratory / Clinical Analyzer Calibrators and Reagents / Reagents / Reagent Kit / Reagent Kit Atellica® IM Cancer BR 27.29 For Atellica® IM Analyzer 50 Tests10995478
Picture of Reagent Kit Atellica® IM Cancer BR 27.29 For Atellica® IM Analyzer 50 Tests10995478

Reagent Kit Atellica® IM Cancer BR 27.29 For Atellica® IM Analyzer 50 Tests10995478

Reagent-Kit-Atellica®-IM-Cancer-BR-27-29-For-Atellica®-IM-Analyzer-50-Tests10995478

SKU #

#1108970

MPN #

10995478

Brand

Siemens

Stock

In Stock

Quantity

100

Features

REAGENT, IMMUNOASSAY ATELLICA BR (50TESTS) D/S

$300.68 USD

Product Specifications Product Usage Additional Information
Print
Attribute Name Attribute Value
McKesson # 1108970
Manufacturer # 10995478
Brand Atellica® IM
Manufacturer Siemens
Application Reagent Kit
For Use With For Atellica® IM Analyzer
Form Liquid
Number of Tests 50 Tests
Sample Type Serum Sample
Storage Requirements Requires Refrigeration
Test Name BR 27.29
Test Type Cancer
Type Chemiluminescent Immunoassay
UNSPSC Code 41116004
Compare Selected Items Email

Similar Items

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

  • The Atellica™ IM BR 27.29 (BR) assay is for in vitro diagnostic use in the quantitative serial determination of cancer antigen CA 27.29 in human serum using the Atellica™ IM Analyzer
  • The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage III breast cancer
  • WARNING: Cancer and Reproductive Harm - www.P65Warnings.ca.gov